| 1 |
dpavlin |
1.1 |
<p align="center"><b>PLIVA finalises acquisition of majority stake in LACHEMA, |
| 2 |
|
|
Czech pharmaceutical company</b></p> |
| 3 |
|
|
<p>Zagreb, December 3, 1999</p> |
| 4 |
|
|
<p>PLIVA today announced that the acquisition of 66,67% stake of the Czech pharmaceutical |
| 5 |
|
|
company, Lachema, was completed yesterday when PLIVA Krakow, PLIVAs subsidiary |
| 6 |
|
|
paid agreed price of USD 26.5 million. Completion follows the agreement that |
| 7 |
|
|
was reached between PLIVA Krakow and Czech institutional investors as announced |
| 8 |
|
|
on 12 November 1999.</p> |
| 9 |
|
|
<p>Lachema is one of the leading Czech pharmaceutical companies. It develops, |
| 10 |
|
|
manufactures and markets pharmaceuticals as well as diagnostic preparations |
| 11 |
|
|
and fine chemicals. Lachemas strength lies in cytostatics. Also, cardiovascular |
| 12 |
|
|
drugs and antivirotics complete the companys current portfolio. Lachemas range |
| 13 |
|
|
of generic cytostatic products and its brand new facility for injectable cytostatics |
| 14 |
|
|
will enable PLIVA to continue its further expansion into this attractive niche |
| 15 |
|
|
market, not only in the CEE region, but into Western markets as well. </p> |
Parent Directory
| 
Revision Log